Effect of dietary advanced glycation end products on mouse liver

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Patel, Raza ^a   Baker, Susan S ^a   Liu, Wensheng ^a   Desai, Sonal ^a   Alkhouri, Razan ^a   Kozielski, Rafal ^a   Mastrandrea, Lucy ^a   Sarfraz, Adil ^a   Cai, Weijing ^b   Vlassara, Helen ^b   Patel, Mulchand S ^a   Baker, Robert D ^a   Zhu, Lixin ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEPATITIS; INSULIN RESISTANCE; LIPID STORAGE; LIVER; LIVER HISTOLOGY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DIET; DIET RESTRICTION; DRUG EFFECT; ENZYMOLOGY; FATTY LIVER; GLUCOSE TOLERANCE TEST; PATHOLOGY;

MUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; DIET; FASTING; FATTY LIVER; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION;

EID: 84859354773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035143     Document Type: Article

References (40)

1. Clark JM, Brancati FL, Diehl AM, (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98: 960-967.
2. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, et al. (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9: 524-530 e521; quiz e560.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
4. Brunt EM, (2004) Nonalcoholic steatohepatitis. Seminars in Liver Disease 24: 3-20.
5. Bugianesi E, Vanni E, Marchesini G, (2007) NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 7: 175-180.
6. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, et al. (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253.
7. Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, et al. (2000) Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 21: 983-989.
8. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, et al. (2000) Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 378: 259-268.
9. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, et al. (2002) In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 37: 56-62.
10. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, et al. (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38: 999-1007.
11. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, et al. (2007) Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 31: S61-66.
12. Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC, (1995) Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol 48: 825-834.
13. Lieber CS, (2004) CYP2E1: from ASH to NASH. Hepatol Res 28: 1-11.
14. Mannaerts GP, Van Veldhoven PP, Casteels M, (2000) Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. Cell Biochem Biophys 32 Spring pp. 73-87.
15. Cope K, Risby T, Diehl AM, (2000) Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119: 1340-1347.
16. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L, (2010) Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 5: e9570.
17. Hyogo H, Yamagishi S, (2008) Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14: 969-972.
18. Singh R, Barden A, Mori T, Beilin L, (2001) Advanced glycation end-products: a review. Diabetologia 44: 129-146.
19. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, et al. (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94: 13915-13920.
20. Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, et al. (1996) Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett 208: 53-56.
21. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, et al. (2008) Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 43: 298-304.
22. Cai W, He JC, Zhu L, Chen X, Wallenstein S, et al. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 170: 1893-1902.
23. Cai W, He JC, Zhu L, Chen X, Zheng F, et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173: 327-336.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
25. Sandu O, Song K, Cai W, Zheng F, Uribarri J, et al. (2005) Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54: 2314-2319.
26. Kim CH, Younossi ZM, (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75: 721-728.
27. Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, et al. (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 91: 1220-1226.
28. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, et al. (2007) Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22: 1112-1119.
29. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, et al. (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6: 998-1003.
30. Anstee QM, Goldin RD, (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16.
31. Day CP, James OF, (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845.
32. Lindenmeier M, Faist V, Hofmann T, (2002) Structural and functional characterization of pronyl-lysine, a novel protein modification in bread crust melanoidins showing in vitro antioxidative and phase I/II enzyme modulating activity. J Agric Food Chem 50: 6997-7006.
33. Vlassara H, (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 (Suppl 2): S19-25.
34. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, et al. (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32: 1218-1220.
35. Wang MY, Ross-Cisneros FN, Aggarwal D, Liang CY, Sadun AA, (2009) Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol 118: 381-389.
36. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, et al. (2004) Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 122: 461-467.
37. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H, (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811.
38. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99: 15596-15601.
39. Chuyen NV, Arai H, Nakanishi T, Utsunomiya N, (2005) Are food advanced glycation end products toxic in biological systems? Ann N Y Acad Sci 1043: 467-473.
40. Tilg H, Moschen AR, (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846.